← Back to Clinical Trials
Recruiting NCT05910580

NCT05910580 Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05910580
Status Recruiting
Phase
Sponsor Emory University
Condition Alcohol-Related Disorders
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2025-07-03
Primary Completion 2027-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Screening, Brief Intervention, and Referral to Treatment (SBIRT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2025-07-03 with a primary completion date of 2027-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic. The main questions it aims to answer are: * Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing? * Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity? * Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)? Participants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months. Researchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.

Eligibility Criteria

Inclusion Criteria: * Over the age of 18 years * U.S. residing * Have internet access (own a computer or smart phone) * Screen positive to one or more risky alcohol and substance use behaviors as determined by our standardized abbreviated instruments Exclusion Criteria: * Not capable of communicating (reading, speaking, writing) in English or Spanish

Contact & Investigator

Central Contact

Kelli S Hall, PhD MS

✉ ksh2110@cumc.columbia.edu

📞 212-305-4805

Principal Investigator

Kelli S Hall, MD

PRINCIPAL INVESTIGATOR

Columbia University

Frequently Asked Questions

Who can join the NCT05910580 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Alcohol-Related Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05910580 currently recruiting?

Yes, NCT05910580 is actively recruiting participants. Contact the research team at ksh2110@cumc.columbia.edu for enrollment information.

Where is the NCT05910580 trial being conducted?

This trial is being conducted at Boston, United States, Marlborough, United States, Springfield, United States, Worcester, United States.

Who is sponsoring the NCT05910580 clinical trial?

NCT05910580 is sponsored by Emory University. The principal investigator is Kelli S Hall, MD at Columbia University. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology